Skip to main content

Table 1 General study characteristics of the models evaluating routine varicella vaccination

From: Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

Study Country Model type Accounting for herd protection Impact of varicella vaccination on HZ incidence Time horizon Type of economic evaluation Perspective Discount rate (costs/health effects) Costing year and currency Funding source
Banz et al. [35] Germany Dynamic Yes No 30 years CC Health care payer; societal 5 %/0 % 1999 EUR Industry
Banz et al. [51] Switzerland Dynamic Yes No 30 years CC; CEA Health care payer; societal 5 %/0 % 2008 CHF Industry
Beutels et al. [37] Germany Static No No 70 years CC; CEA Health care payer; societal 5 %/5 % 1995 DEM Independent
Bilcke et al. [30] Belgium Dynamic Yes Depending on the type of analysis Various CEA; CUA Health care payer 3 %/1.5 % 2010a EUR Independent
Bonanni et al. [36] Italy Dynamic Yes No 30 years CC Health care payer; societal 3 %/0 % 2007a EUR Industry
Brisson et al. [31] Canada Dynamic Yes Yes (only in a separate analysis) 30 years CC; CEA Health care payer; societal 3 %/3 % 1997/1998 CAD Independent
Brisson et al. [32] England and Wales Dynamic Yes Yes 80 years CUA Health care payer; societal 3 %/3 % 2001 GBP Independent
Coudeville et al. [52] France Dynamic Yes No 30 years CC Health care payer; societalb 5 %/NA 1995 FRF Industry
Coudeville et al. [53] Italy Dynamic Yes No 50 years CC Health care payer; societal 3 %/NA 2002 EUR Industry
Coudeville et al. [54] France and Germany Dynamic Yes No 50 years CC; CEA Health care payer; societal 3 %/3 % 2002 EUR Industry
Diez Domingo et al. [55] Spain Static No No 20 years CC Health care payer; societal 5 %/NA 1994 PTA Independent
Getsios et al. [56] Canada Static No No 70 years CEA; CUA Health care payer; societal 3 %/3 % 1998 CAD Independent
Ginsberg & Somekh [57] Israel Static Partially No Lifetime CC Health care payer; societal 3 %/NA 2002 USD Independent
Hammerschmidt et al. [58] Germany Dynamic Yes No 30 years CC Health care payer; societal Not specified (probably 5 % for costs) 1999/2006c EUR Industry
Huse et al. [59] USA Static No No 24 years CC Societal 5 %/5 % 1991 USD Industry
Lenne et al. [60] Spain Dynamic Yes No 50 years CC; CEA Health care payer; societal 3 %/0 % 2004 EUR Industry
Lieu et al. [61] USA Dynamic Yes No 30 years CC; CEA Health care payer; societal 5 %/5 % 1990 USD Independent
Preblud et al. [62] USA Static No No 30 years CC Health care payer; societal 5 %/0 % 1984 USD Independent
Scuffham et al. [63] New Zealand Static No No 30 years CC Health care payer; societal 5 %/5 % 1997 NZD Industry
Scuffham et al. [34] Australia Static No No 30 years CEA Health care payer 5 %/5 % 1996/1997 AUD Independent
Thiry et al. [64] Italy Static No No 100 years CC; CEA Health care payer; societal 3 %/3 % 2002 EUR Industry
van Hoek et al. [33] UK Dynamic Yes Yes Infinite CUA Health care payer 3.5 %/3.5 % 2007 GBP Independent
Zhou et al. [29] USA Static No No Lifetime CC; CUA Health care payer; societal 3 %/3 % 2006 USD Industry
  1. CC cost-comparison; CEA cost-effectiveness analysis; CUA cost-utility analysis; NA = not applicable
  2. aAssumption
  3. bIndirect costs were not evaluated in monetary terms but reported as the number of days of absence from work
  4. cPersonal communication with the author (1999 prices; 2006 vaccine prices)